Lymphoma & Leukaemia Research Review, Issue 35

In this issue:

Infants with ALL treated with the Interfant-06 Protocol
POD24 in follicular lymphoma and reduced intratumoural immune infiltration
Bortezomib added to ofatumumab + bendamustine in follicular lymphoma
IFNα-dendritic cells and rituximab in follicular lymphoma
Obinutuzumab + ibrutinib followed by MRD-driven strategy in CLL
Idarubicin, cytarabine + nivolumab in AML or high-risk MDS
Risk-adapted MRD-driven therapy in AML
Phase 1 study of the selective BTK inhibitor zanubrutinib
Early progression predicts survival in marginal zone lymphomas
A fully human anti-IL-7Rα antibody has antitumor activity in T-cell ALL

Please login below to download this issue (PDF)

Subscribe